Full-Time

Assistant General Counsel

Updated on 9/12/2026

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Cork, Ireland

In Person

Bachelor's

Category
Legal (1)

Get referred to Cencora

See people who can refer or advise you

Requirements
  • A law degree and qualification to practice in Ireland in good standing are required.
  • Seven to ten or more years of post-qualified experience is required, in-house and/or at a leading law firm, with strong experience in commercial contracting and regulated environments.
  • Demonstrated ability to negotiate complex commercial agreements and advise senior stakeholders with clear, pragmatic recommendations is required.
  • Experience supporting corporate governance activities, including Board or committee materials, resolutions, and minutes, is required.
  • Working knowledge of the General Data Protection Regulation and data privacy and security contracting concepts is required, along with the ability to partner effectively with privacy and security stakeholders.
  • Strong communication, organization, presentation, facilitation, and project management skills are required, with the ability to manage multiple priorities in a matrix environment.
  • The role requires management of one or more legal professionals and effective management of direct reports.
  • Strong decision-making capability and the ability to make business-oriented, legally compliant recommendations are required.
  • The ability to manage multiple matters amid change, multitask, focus, and shift priorities to complete work in a timely and efficient manner is required.
Responsibilities
  • Act as Secretary to Cencora Global Procurement and manage Board governance processes, including meeting notices, agendas, presentations, written resolutions, approvals, and meeting minutes.
  • Maintain accurate corporate records and ensure compliance with the Companies Act 2014 requirements, including CRO filings and updates, while keeping governance documentation complete, controlled, and accessible for audit and regulatory needs.
  • Draft, review, negotiate, and advise on pharmaceutical manufacturer-facing agreements to align with Cencora Global Procurement strategy and objectives while minimizing legal, regulatory, and reputational risk.
  • Provide escalation support for non-standard risk positions and ensure appropriate internal review, approvals, and documentation.
  • Support commercial negotiators on manufacturer-facing matters and intercompany agreements, including global contracting strategy, contract language and provision review, negotiations, and internal or external risk assessments.
  • Develop and maintain standard templates, clause guidance, and negotiation playbooks to drive consistency and speed.
  • Lead matters requiring project management capability, including integrated legal and business ownership of contract programs and strategic initiatives supporting Cencora Global Procurement goals.
  • Drive stakeholder alignment, timelines, decision-making, and delivery of outcomes across workstreams.
  • Support Cencora Global Procurement compliance with privacy and security policies and requirements, including the General Data Protection Regulation and relevant United States data privacy laws and requirements.
  • Collaborate with the Privacy team and outside counsel on privacy compliance, contractual privacy terms, and implementation of required controls.
  • Assist in managing delivery of legal services across Cencora Global Procurement, including employment and human resources, immigration, intellectual property, litigation and disputes, and compliance matters.
  • Coordinate the retention and oversight of outside counsel, including scope management, quality control, and budget awareness.
  • Drive legal strategy and support regulatory compliance obligations as Cencora Global Procurement expands into additional jurisdictions.
  • Monitor legislative, judicial, and regulatory developments affecting Cencora Global Procurement operations and advise leadership on impact, options, and recommended actions.
  • Identify, assess, and mitigate legal risks; advise management on risk trade-offs and implement practical mitigation plans.
  • Maintain strong documentation and escalation practices for key decisions, risks, and approvals.
  • Perform related duties as assigned and required by Cencora Global Procurement.
Desired Qualifications
  • Experience in the pharmaceuticals or life sciences industry, including manufacturer-facing, distribution, services, or broader healthcare experience.
  • Familiarity with United States law relevant to Cencora Global Procurement operations and cross-border data considerations.
  • Experience managing outside counsel across multiple jurisdictions and practice areas.
  • Previous line-management experience and the ability to lead, motivate, and develop others.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fiscal 2026 Q3 revenue reached $84.8 billion, and EPS guidance rose to $17.75-$17.95.
  • Cencora completed OneOncology in February 2026, strengthening specialty-pharmacy and oncology economics.
  • A $7 billion revolver and $1 billion buyback show lenders and management backing execution.

What critics are saying

  • Opioid litigation still carries a $4.2 billion accrued liability through 2039.
  • Maryland courts vacated Baltimore's $152 million verdict, but appeals can revive distributor exposure.
  • ASP rule changes and 340B guidance threaten community-oncology margins by 2028, hitting OneOncology.

What makes Cencora unique

  • Cencora pairs drug distribution with OneOncology, deepening specialty-care workflow integration.
  • Its global network spans U.S. Healthcare Solutions and International Healthcare Solutions across 51,000 employees.
  • Nucleus inventory tools and cell-gene therapy enablement embed Cencora inside provider operations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Company News

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.

MarketScreener
Aug 5th, 2026
Cencora boosts credit facility to $7B, extends maturity to 2031

Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.

Yahoo Finance
Aug 1st, 2026
Cencora Q3 earnings preview: analysts expect $4.37 EPS on $84.89B revenue

Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.